MetaCap

Azora Therapeutics (AZR) vs Boundless Bio (BOLD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Azora Therapeutics is the larger company by market cap ($55.0 million vs $54.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZR-24.51%BOLD-7.20%
+2%-16%-33%
Oct 28, 20261 yearNov 20, 2026
AZR+1.05%BOLD-6.07%
+8%+1%-7%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZR versus BOLD key metrics
MetricAZRBOLD
Share price$3.85$2.32
Market cap$55.00M$54.78M
1-day change-0.52%-2.52%
YTD return—+93.33%
1-year return—+105.31%
EPS (TTM)$-18.09$-2.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.98M$-58.20M
52-week high$8.25$3.16
52-week low$1.31$0.961
Distance from 52-week high-53.33%-26.68%
Analyst consensus—none
Avg. price target upside—+72.41%
Average volume50.12K131.34K
Shares outstanding14.29M23.61M
Employees—28
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

AZR vs BOLD FAQ

Which is bigger, Azora Therapeutics or Boundless Bio?

Azora Therapeutics (AZR) is larger, with a market capitalization of $55.00M compared with $54.78M for Boundless Bio (BOLD).

Are Azora Therapeutics and Boundless Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons